About medincell sa - MDCLF
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. It focuses on combining its proprietary BEPO technology with active ingredients already known and marketed; it controls the regular delivery of a drug at the optimal therapeutic dose. The company was founded by Anh Nguyen and Christophe Douat on January 9, 2003 and is headquartered in Jacou, France.
MDCLF At a Glance
MedinCell SA
3, rue des Frères Lumière
Jacou, Occitanie 34830
| Phone | N/A | Revenue | 27.29M | |
| Industry | Pharmaceuticals: Major | Net Income | -19,794,263.99 | |
| Sector | Health Technology | 2025 Sales Growth | 178.658% | |
| Fiscal Year-end | 03 / 2026 | Employees | 140 | |
| View SEC Filings |
MDCLF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.892 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 22.41 |
| Enterprise Value to EBITDA | -37.135 |
| Enterprise Value to Sales | 16.372 |
| Total Debt to Enterprise Value | 0.142 |
MDCLF Efficiency
| Revenue/Employee | 194,919.807 |
| Income Per Employee | -141,387.60 |
| Receivables Turnover | 3.295 |
| Total Asset Turnover | 0.397 |
MDCLF Liquidity
| Current Ratio | 2.699 |
| Quick Ratio | 2.699 |
| Cash Ratio | 2.407 |
MDCLF Profitability
| Gross Margin | N/A |
| Operating Margin | -51.914 |
| Pretax Margin | -80.987 |
| Net Margin | -72.536 |
| Return on Assets | -28.769 |
| Return on Equity | N/A |
| Return on Total Capital | -43.228 |
| Return on Invested Capital | -77.86 |
MDCLF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 138.61 |
| Total Debt to Total Assets | 64.96 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 121.403 |